Is your hospital ready for mandatory CMS reporting on inpatient glycemic safety? → Find out by taking our CMS Glycemic Safety Readiness Assessment.
: Customer outcomes.
At Glooko, we are incredibly proud of the achievements of EndoTool in safely reducing hyperglycemia and hypoglycemia rates across hospitals nationwide.
Latest customer outcomes
Unlike traditional glucose management systems that don’t account for variability between patients, EndoTool’s algorithm adjusts to each patient's unique characteristics and response to insulin. This patient-specific approach ensures optimal insulin dosing recommendations, which is especially crucial for patients with reduced renal function.
With EndoTool, reduce the risk of severe hypoglycemia to virtually zero.
| Metric | eGFR < 20 | eGFR > 60 | Notes |
|---|---|---|---|
| Severe Hypoglycemia Rate (<40 mg/dL) | 0.013% | 0.006% | Exceptionally low, ensuring patient safety |
| Hypoglycemia Rate (<70 mg/dL) | 0.35% | 0.24% | Slightly lower in patients with better renal function, yet within a safe threshold for both groups |
| Severe Hyperglycemia Rate Glucose > 300 mg/dL after goal | 0.36% | 0.37% | Low across all renal functions |
| Time to goal (hrs) | 7.5 | 6.7 | Similar in both groups indicating efficient management across all renal functions |
| Time on drip (hrs) | 27.8 | 25.8 | Shorter duration on drip for patients without renal impairment suggests efficient stabilization |
Source: 2025 EndoTool IV customer outcome data available on file.
Understanding EndoTool outcome data
The Estimated Residual Extracellular Insulin (EREI) feature of EndoTool marks a significant advancement in glucose management by calculating dosing recommendations based on the estimated amount of residual circulating insulin.
This capability is critical in preventing excessive insulin administration, significantly reducing the risk of hypoglycemia, especially in patients with kidney failure.
EREI is the unique feature that makes EndoTool the most reliable product on the market.
For patients at risk of hypoglycemia, EndoTool proactively predicts downward blood glucose trajectories, recommending timely interventions with the administration of specific amounts of oral or intravenous carbohydrates. This approach prevents hypoglycemia and avoids potential rebound hyperglycemia, establishing a new benchmark in patient-specific dosing and predictive modeling.
Partnering for patient safety
Your mission to provide safe patient care is our top priority. At Glooko, we are your partner in enhancing patient outcomes and operational efficiency.
Proven trackrecord
EndoTool has been implemented in hundreds of hospitals across the United States, managing more than 3,800 dosing calculations every day.
Clinically
validated
Studies published in peer-reviewed medical journals demonstrate that EndoTool reduces the incidence of both hypo and hyperglycemia in diverse patient populations.
Regulatory compliance
Fully compliant with FDA regulations and continuously updated to meet the highest standards of medical software safety and effectiveness.
High user satisfaction
95% of our clients report significant improvements in patient glucose management and overall satisfaction with the system’s performance.
Get in Touch
Ready to get started?
Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.
"*" indicates required fields
